Medical - Healthcare Information Services
Compare Stocks
4 / 10Stock Comparison
TDOC vs DBVT vs ALKS vs AMWL
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Healthcare Information Services
TDOC vs DBVT vs ALKS vs AMWL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Biotechnology | Biotechnology | Medical - Healthcare Information Services |
| Market Cap | $1.26B | $1712.35T | $5.90B | $129M |
| Revenue (TTM) | $2.51B | $0.00 | $1.56B | $182M |
| Net Income (TTM) | $-171M | $-168M | $153M | $-88M |
| Gross Margin | 65.6% | — | 65.4% | 38.7% |
| Operating Margin | -7.6% | — | 12.3% | -50.6% |
| Forward P/E | — | — | 24.8x | — |
| Total Debt | $1.04B | $22M | $70M | $5M |
| Cash & Equiv. | $781M | $194M | $1.12B | $182M |
TDOC vs DBVT vs ALKS vs AMWL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Teladoc Health, Inc. (TDOC) | 100 | 3.2 | -96.8% |
| DBV Technologies S.… (DBVT) | 100 | 115.5 | +15.5% |
| Alkermes plc (ALKS) | 100 | 213.6 | +113.6% |
| American Well Corpo… (AMWL) | 100 | 1.3 | -98.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TDOC vs DBVT vs ALKS vs AMWL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TDOC is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth -1.5%, EPS growth 80.6%, 3Y rev CAGR 1.7%
- -1.5% revenue growth vs DBVT's -100.0%
- Better valuation composite
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs TDOC's +1.5%
ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -11.0% 10Y total return vs TDOC's -41.1%
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
- 9.8% margin vs AMWL's -48.2%
AMWL lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -1.5% revenue growth vs DBVT's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.8% margin vs AMWL's -48.2% | |
| Stability / Safety | Beta 1.06 vs TDOC's 1.91, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs TDOC's +1.5% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
TDOC vs DBVT vs ALKS vs AMWL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
TDOC vs DBVT vs ALKS vs AMWL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 3 of 6 categories
TDOC leads 1 • DBVT leads 1 • AMWL leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TDOC and DBVT operate at a comparable scale, with $2.5B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $2.5B | $0 | $1.6B | $182M |
| EBITDAEarnings before interest/tax | $42M | -$112M | $212M | -$59M |
| Net IncomeAfter-tax profit | -$171M | -$168M | $153M | -$88M |
| Free Cash FlowCash after capex | $251M | -$151M | $392M | -$42M |
| Gross MarginGross profit ÷ Revenue | +65.6% | — | +65.4% | +38.7% |
| Operating MarginEBIT ÷ Revenue | -7.6% | — | +12.3% | -50.6% |
| Net MarginNet income ÷ Revenue | -6.8% | — | +9.8% | -48.2% |
| FCF MarginFCF ÷ Revenue | +10.0% | — | +25.1% | -22.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.5% | — | +28.2% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +32.1% | +91.5% | -4.1% | +44.5% |
Valuation Metrics
TDOC leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, TDOC's 15.1x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.3B | $1712.35T | $5.9B | $129M |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $1712.35T | $4.9B | -$48M |
| Trailing P/EPrice ÷ TTM EPS | -6.11x | -0.76x | 24.76x | -1.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 15.13x | — | 17.25x | — |
| Price / SalesMarket cap ÷ Revenue | 0.50x | — | 4.00x | 0.52x |
| Price / BookPrice ÷ Book value/share | 0.89x | 0.66x | 3.28x | 0.50x |
| Price / FCFMarket cap ÷ FCF | 4.40x | — | 12.28x | — |
Profitability & Efficiency
ALKS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to TDOC's 0.75x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -12.4% | -130.2% | +8.8% | -33.5% |
| ROA (TTM)Return on assets | -5.9% | -89.0% | +5.4% | -25.1% |
| ROICReturn on invested capital | -11.5% | — | +18.9% | -95.1% |
| ROCEReturn on capital employed | -10.0% | -145.7% | +14.2% | -36.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.75x | 0.13x | 0.04x | 0.02x |
| Net DebtTotal debt minus cash | $259M | -$172M | -$1.0B | -$178M |
| Cash & Equiv.Liquid assets | $781M | $194M | $1.1B | $182M |
| Total DebtShort + long-term debt | $1.0B | $22M | $70M | $5M |
| Interest CoverageEBIT ÷ Interest expense | -8.76x | -189.82x | 32.30x | -239.18x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, DBVT leads with a +110.4% total return vs TDOC's +1.5%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs AMWL's -42.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -1.3% | +4.9% | +25.3% | +59.8% |
| 1-Year ReturnPast 12 months | +1.5% | +110.4% | +16.5% | +14.3% |
| 3-Year ReturnCumulative with dividends | -73.3% | +19.7% | +14.5% | -80.7% |
| 5-Year ReturnCumulative with dividends | -95.4% | -69.1% | +60.9% | -97.2% |
| 10-Year ReturnCumulative with dividends | -41.1% | -87.0% | -11.0% | -98.3% |
| CAGR (3Y)Annualised 3-year return | -35.6% | +6.2% | +4.6% | -42.2% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than TDOC's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs TDOC's 71.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 1.26x | 1.06x | 1.47x |
| 52-Week HighHighest price in past year | $9.77 | $26.18 | $36.60 | $9.15 |
| 52-Week LowLowest price in past year | $4.40 | $7.53 | $25.17 | $3.71 |
| % of 52W HighCurrent price vs 52-week peak | +71.2% | +76.3% | +96.7% | +84.7% |
| RSI (14)Momentum oscillator 0–100 | 74.1 | 48.1 | 60.2 | 67.1 |
| Avg Volume (50D)Average daily shares traded | 5.5M | 252K | 2.3M | 59K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: TDOC as "Hold", DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 8.9% for TDOC (target: $8).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | — |
| Price TargetConsensus 12-month target | $7.58 | $46.33 | $44.00 | — |
| # AnalystsCovering analysts | 42 | 15 | 28 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | +0.0% |
ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TDOC leads in 1 (Valuation Metrics).
TDOC vs DBVT vs ALKS vs AMWL: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is TDOC or DBVT or ALKS or AMWL a better buy right now?
For growth investors, Teladoc Health, Inc.
(TDOC) is the stronger pick with -1. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TDOC or DBVT or ALKS or AMWL?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TDOC or DBVT or ALKS or AMWL?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
06β versus Teladoc Health, Inc. 's 1. 91β — meaning TDOC is approximately 80% more volatile than ALKS relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TDOC or DBVT or ALKS or AMWL?
By revenue growth (latest reported year), Teladoc Health, Inc.
(TDOC) is pulling ahead at -1. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TDOC or DBVT or ALKS or AMWL?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -38. 4% for American Well Corporation — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TDOC or DBVT or ALKS or AMWL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TDOC or DBVT or ALKS or AMWL better for a retirement portfolio?
For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
06)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TDOC and DBVT and ALKS and AMWL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.